Avanafil: Difference between revisions

	WikiDoc Resources for Avanafil
Articles
Most recent articles on Avanafil Most cited articles on Avanafil Review articles on Avanafil Articles on Avanafil in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Avanafil Images of Avanafil Photos of Avanafil Podcasts & MP3s on Avanafil Videos on Avanafil
Evidence Based Medicine
Cochrane Collaboration on Avanafil Bandolier on Avanafil TRIP on Avanafil
Clinical Trials
Ongoing Trials on Avanafil at Clinical Trials.gov Trial results on Avanafil Clinical Trials on Avanafil at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Avanafil NICE Guidance on Avanafil NHS PRODIGY Guidance FDA on Avanafil CDC on Avanafil
Books
Books on Avanafil
News
Avanafil in the news Be alerted to news on Avanafil News trends on Avanafil
Commentary
Blogs on Avanafil
Definitions
Definitions of Avanafil
Patient Resources / Community
Patient resources on Avanafil Discussion groups on Avanafil Patient Handouts on Avanafil Directions to Hospitals Treating Avanafil Risk calculators and risk factors for Avanafil
Healthcare Provider Resources
Symptoms of Avanafil Causes & Risk Factors for Avanafil Diagnostic studies for Avanafil Treatment of Avanafil
Continuing Medical Education (CME)
CME Programs on Avanafil
International
Avanafil en Espanol Avanafil en Francais
Business
Avanafil in the Marketplace Patents on Avanafil
Experimental / Informatics
List of terms related to Avanafil

Avanafil
	File:Avanafil.svg
Clinical data
Routes of; administration	Oral
Identifiers
	IUPAC name 4-[(3-Chloro-4-methoxybenzyl)amino]-2- [2-(hydroxymethyl)-1-pyrrolidinyl]-N- (2-pyrimidinylmethyl)-5-pyrimidinecarboxamide;
CAS Number	330784-47-9;
PubChem CID	9869929;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H26ClN7O3
Molar mass	483.951 g/mol

Revision as of 22:39, 8 August 2012

Avanafil is a PDE5 inhibitor being developed for erectile dysfunction.

@@ Line 27: / Line 27: @@
 }}
 {{SI}}
-{{EH}}
 '''Avanafil''' is a [[PDE5 inhibitor]] being developed for [[erectile dysfunction]].
@@ Line 33: / Line 33: @@
 {{Urologicals}}
 {{Phosphodiesterase inhibitors}}
-{{SIB}}
 [[Category:Phosphodiesterase inhibitors]]

v t e Urologicals (G04)
Acidifiers	Ammonium chloride, Calcium chloride
Urinary antispasmodics (primarily antimuscarinics)	Darifenacin, Emepronium, Fesoterodine, Flavoxate, Meladrazine, Oxybutynin, Propiverine, Solifenacin, Terodiline, Tolterodine, Trospium
For erectile dysfunction	prostaglandins: Alprostadil PDE5 inhibitors: Avanafil - Sildenafil - Tadalafil - Udenafil - Vardenafil alpha blockers: Moxisylyte - Phentolamine - Yohimbine others: Apomorphine - Papaverine
Other urologicals	Acetohydroxamic acid, Collagen, Dimethyl sulfoxide, Magnesium hydroxide, Pentosan polysulfate, Phenazopyridine, Phenyl salicylate, Succinimide
For benign prostatic hypertrophy	5α-reductase inhibitors: Dutasteride, Finasteride Alpha blockers: Alfuzosin, Doxazosin, Silodosin, Tamsulosin, Terazosin Herbals: Pygeum africanum, Serenoa repens

Clinical data
File:Avanafil.svg
Routes of administration	Oral
Identifiers
IUPAC name 4-[(3-Chloro-4-methoxybenzyl)amino]-2- [2-(hydroxymethyl)-1-pyrrolidinyl]-N- (2-pyrimidinylmethyl)-5-pyrimidinecarboxamide
CAS Number	330784-47-9
PubChem CID	9869929
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₂₆ClN₇O₃
Molar mass	483.951 g/mol